This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors
by Zacks Equity Research
Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
by Zacks Equity Research
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold
by Zacks Equity Research
With the FDA's clinical hold, no new studies can be initiated on Merck's (MRK) islatravir. While six studies on islatravir have been placed on full clinical hold, seven have been put on partial clinical hold.
Bristol-Myers (BMY) Up on Dividend Hike, Share Repurchase
by Zacks Equity Research
Bristol-Myers (BMY) increases its quarterly dividend and announces a share repurchase program. Consequently, the stock gains.
Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?
by Kinjel Shah
The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $72.62, marking a -0.33% move from the previous day.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
by Zacks Equity Research
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies
by Zacks Equity Research
Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
by Zacks Equity Research
Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Bristol Myers (BMY) sBLA for Reblozyl Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
by Zacks Equity Research
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan
by Kinjel Shah
FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe
Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
by Zacks Equity Research
Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
by Zacks Equity Research
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.
Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
by Zacks Equity Research
The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.